Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 17/20 | 0.53 |
| ▸ | CDK2 | P24941 | 17/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 14/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22311475 | 1.00 | CCNE1 (0.53) | CCNE1CDK2MEN1KMT2ANPC1 | |
| SCHEMBL30519060 | 0.82 | CCNE1 (0.49) | CCNE1CDK2MEN1KMT2ANPC1 | |
| SCHEMBL22310677 | 0.81 | CCNE1 (0.58) | CCNE1CDK2GSK3B | |
| SCHEMBL30519180 | 0.81 | CCNE1 (0.56) | CCNE1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL3421180 | 0.78 | SMN1; SMN2 (0.57) | MEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL22311148 | 0.78 | CDK2 (0.71) | CCNE1CDK2GSK3B | |
| SCHEMBL2495046 | 0.76 | MEN1 (0.55) | MEN1KMT2ANPC1LMNAPKM | |
| SCHEMBL22286733 | 0.76 | CCNE1 (0.68) | CCNE1CDK2GSK3B | |
| SCHEMBL22286798 | 0.76 | CCNE1 (0.68) | CCNE1CDK2GSK3B | |
| SCHEMBL3424677 | 0.75 | GAA (0.57) | CCNE1CDK2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-11718603-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718603-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885MEN1 874/4885 |
| US-20240294506-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | CCNE1 8/4885CDK2 1/4885MEN1 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.